keyword
MENU ▼
Read by QxMD icon Read
search

Defibrotide

keyword
https://www.readbyqxmd.com/read/27892944/veno-occlusive-disease-sinusoidal-obstruction-syndrome-after-haematopoietic-stem-cell-transplantation-middle-east-north-africa-regional-consensus-on-prevention-diagnosis-and-management
#1
A H Al Jefri, H Abujazar, A Al-Ahmari, A Al Rawas, Z Al Zahrani, A Alhejazi, M A Bekadja, A Ibrahim, M Lahoucine, S Ousia, A Bazarbachi
Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) of the liver is a serious, early complication of haematopoietic stem cell transplantation (HSCT), severe and very severe forms of which are associated with a high mortality rate. A wide variety of patient, disease and treatment-related risk factors for VOD/SOS have been identified. Several bodies have published recommendations for the diagnosis, prevention and management of VOD/SOS following HSCT. A group of regional experts have developed a consensus statement on the diagnosis, prevention and management of VOD/SOS in the Middle East and North Africa region to help in the management of HSCT patients in the region...
November 28, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27870480/pharmacokinetics-and-safety-of-defibrotide-in-healthy-japanese-subjects
#2
Kazuo Umemura, Takayuki Iwaki, Toshimi Kimura, Chitose Ogawa, Takahiro Fukuda, Shuichi Taniguchi, Keizo Horibe, Hiroaki Goto, Kenichi Yoshimura, Yasutaka Watanabe, Chika Nitani, Atsushi Kikuta
No abstract text is available yet for this article.
November 2016: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27843363/defibrotide-in-the-treatment-of-hepatic-veno-occlusive-disease
#3
REVIEW
Alessandro Fulgenzi, Maria Elena Ferrero
Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), represents the most frequent complication in patients in early phase following hematopoietic stem-cell transplantation (HSCT). In its severe form, VOD/SOS can be associated with multiorgan failure and with a mortality rate >80% by day +100. Defibrotide (DF) (a mixture of 90% single-stranded phosphodiester oligonucleotides and 10% double-stranded phosphodiester oligonucleotides derived from controlled depolarization of porcine intestinal mucosal DNA) has been proposed for the treatment of SOS due to its ability to restore thrombo-fibrinolytic balance and protect endothelial cells...
2016: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/27721142/defibrotide-for-the-management-of-sinusoidal-obstruction-syndrome-in-patients-who-undergo-haemopoietic-stem-cell-transplantation
#4
John Coutsouvelis, Sharon Avery, Michael Dooley, Carl Kirkpatrick, Andrew Spencer
Sinusoidal obstruction syndrome, previously known as veno-occlusive disease (VOD/SOS), is a complication in patients undergoing haemopoietic stem cell transplantation (HSCT). Severe VOD/SOS, including progression to multi-organ failure, has resulted in a mortality of greater than 80%. Defibrotide's varying pharmacological actions, particularly on endothelial cells, make it is a useful agent to consider for prophylaxis and treatment of VOD/SOS. Barriers to its routine use include the high acquisition cost and the fact that neither the oral or parenteral formulations are licensed products in many countries at this time...
September 30, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27603963/in-brief-defibrotide-defitelio-for-hepatic-veno-occlusive-disease
#5
(no author information available yet)
No abstract text is available yet for this article.
September 12, 2016: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/27574402/pharmacokinetic-profile-of-defibrotide-in-patients-with-renal-impairment
#6
Paola Tocchetti, Elena Tudone, Jean-Francois Marier, Thomas C Marbury, Katie Zomorodi, Mark Eller
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable, potentially life-threatening complication of hematopoietic stem cell transplant conditioning. Severe VOD/SOS, generally associated with multiorgan dysfunction (pulmonary or renal dysfunction), may be associated with >80% mortality. Defibrotide, recently approved in the US, has demonstrated efficacy treating hepatic VOD/SOS with multiorgan dysfunction. Because renal impairment is prevalent in patients with VOD/SOS, this Phase I, open-label, two-part study in adults examined the effects of hemodialysis and severe or end-stage renal disease (ESRD) on defibrotide pharmacokinetics (PK)...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27559192/sugammadex
#7
Dennis J Cada, Terri L Levien, Danial E Baker
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers...
July 2016: Hospital Pharmacy
https://www.readbyqxmd.com/read/27531791/-delayed-hepatic-veno-occlusive-disease-after-haploidentical-hematopoietic-stem-cell-transplantation-a-report-of-six-cases
#8
Hui-Zhu Kang, Xiao-Li Zheng, Zhi-Dong Wang, Dong-Mei Han, Li Ding, Heng-Xiang Wang
OBJECTIVE: To evaluate the morbidity, risk factors, clinical characterisitics, treatments and prognosis of delayed hepatic veno-occlusive disease(HVOD) after haploidentical hematopoietic stem cell transplantation (hi-HSCT). METHODS: The clinical data of 208 patients undergoing hi-HSCT were retrospectively analyzed. RESULTS: Six patients were diagnosed with delayed VOD, among them 4 patients were moderate VOD and 2 patients were severe VOD...
August 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/27496218/high-variability-in-the-reported-management-of-hepatic-veno-occlusive-disease-in-children-after-hematopoietic-stem-cell-transplantation
#9
Micah A Skeens, Jennifer McArthur, Ira M Cheifetz, Christine Duncan, Adrienne G Randolph, Joseph Stanek, Leslie Lehman, Rajinder Bajwa
Veno-occlusive disease (VOD) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). Patients with VOD are often critically ill and require close collaboration between transplant physicians and intensivists. We surveyed members of a consortium of pediatric intensive care unit (PICU) and transplant physicians to assess variability in the self-reported approach to the diagnosis and management of VOD. An internet-based self-administered survey was sent to pediatric HSCT and PICU providers from September 2014 to February 2015...
October 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27408516/pharmaceutical-approval-update
#10
Mary Choy
Defibrotide sodium (Defitelio) for hepatic veno-occlusive disease; emtricitabine/tenofovir alafenamide (Descovy) for human immunodeficiency virus infection; and infliximabdyyb (Inflectra) for Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
July 2016: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/27397724/defibrotide-for-the-treatment-of-hepatic-veno-occlusive-disease-final-results-from-the-international-compassionate-use-program
#11
Selim Corbacioglu, Enric Carreras, Mohamad Mohty, Antonio Pagliuca, Jaap Jan Boelens, Gandhi Damaj, Massimo Iacobelli, Dietger Niederwieser, Eduardo Olavarría, Felipe Suarez, Tapani Ruutu, Leo Verdonck, Robin Hume, Bijan Nejadnik, Chinglin Lai, Giorgia Finetto, Paul Richardson
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable and potentially fatal complication of hematopoietic cell transplantation (HCT) or nontransplantation-associated chemotherapy/radiotherapy. In cases of severe hepatic VOD/SOS, typically defined by associated multiorgan failure (MOF, also known as multiorgan dysfunction), mortality exceeds 80%. Preclinical and early clinical data have provided a rationale for defibrotide treatment in hepatic VOD/SOS. Based on this evidence and in recognition of the dismal prognosis for these patients, defibrotide was made available through an international multicenter compassionate-use program conducted from December 1998 to March 2009...
October 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27384426/mesenchymal-stromal-cells-protect-endothelial-cells-from-cytotoxic-t-lymphocyte-induced-lysis
#12
E F Cahill, T Sax, I Hartmann, S Haffner, E Holler, B Holler, R Huss, C Günther, O Parolini, W Kolch, G Eissner
The integrity of the vasculature plays an important role in the success of allogeneic organ and haematopoietic stem cell transplantation. Endothelial cells (EC) have previously been shown to be the target of activated cytotoxic T lymphocytes (CTL) resulting in extensive cell lysis. Mesenchymal stromal cells (MSC) are multipotent cells which can be isolated from multiple sites, each demonstrating immunomodulatory capabilities. They are explored herein for their potential to protect EC from CTL-targeted lysis...
September 2016: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/27111044/incidence-and-management-of-hepatic-severe-veno-occlusive-disease-in-273-patients-in-a-single-centre-with-defibrotide
#13
R R Pol, N Russell, E Das-Gupta, L Watson, L Rachael, J Byrne
No abstract text is available yet for this article.
September 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27108694/defibrotide-for-treatment-of-severe-veno-occlusive-disease-in-pediatrics-and-adults-an-exploratory-analysis-using-data-from-the-center-for-international-blood-and-marrow-transplant-research
#14
Christopher Strouse, Paul Richardson, Grant Prentice, Sandra Korman, Robin Hume, Bijan Nejadnik, Mary M Horowitz, Wael Saber
Veno-occlusive disease (VOD) is an early and serious complication of hematopoietic cell transplantation (HCT) that is associated with inferior survival, particularly when it is complicated by multiorgan failure (severe VOD). We evaluated the efficacy of defibrotide in the treatment of severe VOD using observational data from the Center for International Blood and Marrow Transplant Research (CIBMTR). Eight thousand three hundred forty-one patients treated by HCT between 2008 and 2011 were identified from the CIBMTR clinical database; 3...
July 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27034141/severe-hepatic-sinusoidal-obstruction-syndrome-in-a-child-receiving-vincristine-actinomycin-d-and-cyclophosphamide-for-rhabdomyosarcoma-successful-treatment-with-defibrotide
#15
Aery Choi, Young Kyung Kang, Sewon Lim, Dong Ho Kim, Jung Sub Lim, Jun Ah Lee
Hepatic sinusoidal obstruction syndrome (SOS) is a life-threatening syndrome that generally occurs as a complication after hematopoietic stem cell transplantation (HSCT), or, less commonly, after conventional chemotherapy. Regarding SOS in rhabdomyosarcoma patients who received conventional chemotherapy, the doses of chemotherapeutic agents are associated with the development of SOS. Several cases of SOS in rhabdomyosarcoma patients after receiving chemotherapy with escalated doses of cyclophosphamide have been reported...
March 30, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/26995745/emerging-therapies-in-antiphospholipid-syndrome
#16
REVIEW
Danieli Andrade, Maria Tektonidou
Antiphospholipid syndrome (APS) is a hypercoagulable state characterized by arterial and venous thromboses and pregnancy morbidity in the presence of antiphospholipid antibodies. Although warfarin remains the main therapeutic choice in APS, there is still concern about its efficacy, safety, and patient compliance. Patients with refractory APS to conventional therapy as well as patients with non-classical manifestations of APS may have alternative treatment approaches. APS pathogenesis has been further elucidated over the past years identifying new molecules as potential new treatment targets...
April 2016: Current Rheumatology Reports
https://www.readbyqxmd.com/read/26922995/does-defibrotide-prophylaxis-decrease-the-risk-of-acute-graft-versus-host-disease-following-allogeneic-hematopoietic-cell-transplantation
#17
Emre Tekgündüz, Ali Hakan Kaya, Sinem Civriz Bozdağ, Şerife Koçubaba, Ömür Kayıkçı, Sinem Namdaroğlu, Bilge Uğur, Seval Akpınar, Hikmetullah Batgi, Filiz Bekdemir, Fevzi Altuntaş
There is some preliminary evidence, that veno-occlusive disease prophylaxis with defibrotide (DF) may also have a role in decreasing risk of acute graft-versus-host disease (aGvHD) by preventing tissue damage. In this study, we aimed to investigate the role of DF prophylaxis on the development of aGvHD at D+180. One hundred ninety-five consecutive adult patients receiving allogeneic HCT were retrospectively evaluated in 3 groups: no DF, DF/post-HCT (DF D+1 to D+14) and DF/pre-HCT (DF for 14 days concurrently with conditioning)...
February 2016: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/26594726/defibrotide-defitelio-an-antithrombotic-drug-with-too-many-uncertainties-in-hepatic-veno-occlusive-disease
#18
(no author information available yet)
No abstract text is available yet for this article.
October 2015: Prescrire International
https://www.readbyqxmd.com/read/26588711/treatment-for-superficial-infusion-thrombophlebitis-of-the-upper-extremity
#19
REVIEW
Marcello Di Nisio, Frank Peinemann, Ettore Porreca, Anne W S Rutjes
BACKGROUND: Although superficial thrombophlebitis of the upper extremity represents a frequent complication of intravenous catheters inserted into the peripheral veins of the forearm or hand, no consensus exists on the optimal management of this condition in clinical practice. OBJECTIVES: To summarise the evidence from randomised clinical trials (RCTs) concerning the efficacy and safety of (topical, oral or parenteral) medical therapy of superficial thrombophlebitis of the upper extremity...
November 20, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26532907/defibrotide-in-veno-occlusive-disease-in-public-hospitals-of-paris-funding-issues-and-perspectives
#20
J Steelandt, F Bocquet, I Fusier, A Cordonnier, P Paubel
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
86595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"